CLASS II Drug recall · Reported 25 Sep 2019 · FDA Enforcement Report

Anagrelide Capsules, USP, 5 mg recalled by Torrent Pharma

Torrent Pharma is recalling Anagrelide Capsules, USP, 5 mg, distributed nationwide in the US. The recall was initiated on 6 Sep 2019 and the FDA has classified it as Class II.

Check your package

Lot, batch or date codesLot #: BFE2E003, Exp 08/31/2020
NDC13668-453, 13668-462
Quantity recalled2472 bottles

Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.

Recall details

Recall number
D-1862-2019
FDA event ID
83733
Recalling firm
Torrent Pharma, Basking Ridge, NJ
Manufacturer
Torrent Pharmaceuticals Limited
Classification
Class II
Status
Terminated
Recall initiated
6 Sep 2019
FDA classified
16 Sep 2019
Reported
25 Sep 2019
Type
Voluntary: Firm initiated
Customers notified by
Letter
Reason category
Potency & Assay

Timeline

6 Sep 2019Recall initiated by company
16 Sep 2019Classified by FDA+10 days
25 Sep 2019Published in enforcement report+9 days

Companies usually start a recall weeks before the FDA classifies and publishes it; the gap above is that lag.

Reason for recall

Failed Impurities/Degradation Specifications: High Out Of Specification results for impurities detected during routine stability testing.

Potency and specification recalls happen when a batch tests outside its approved limits for strength, purity or dissolution, which can mean the dose delivered is higher or lower than labelled.

Product as listed by the FDA

Anagrelide Capsules, USP, 0.5 mg, 100-count bottle, Rx only, Manufactured in India for: Torrent Pharma Inc., Basking Ridge, NJ 07920, NDC 13668-453-01.

Where it was distributed

Nationwide in the USA and Puerto Rico

Nationwide Puerto Rico

Questions about this recall

Is Anagrelide Capsules, USP, 5 mg recalled?

Yes. Torrent Pharma recalled Anagrelide Capsules, USP, 5 mg on 6 Sep 2019. The recall is Class II and its status is Terminated. Recall number D-1862-2019.

Why was it recalled?

Failed Impurities/Degradation Specifications: High Out Of Specification results for impurities detected during routine stability testing.

Which lots are affected?

Lot #: BFE2E003, Exp 08/31/2020

Where was it sold?

Nationwide in the USA and Puerto Rico

What should I do if I have it?

Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.

What does Class II mean?

Class II means the product may cause temporary or medically reversible health problems, or the probability of serious harm is remote.

Read the official FDA notice · Source record retrieved 21 Sep 2026. The FDA describes openFDA data as unvalidated; the official notice takes precedence. This page reports the record and gives no medical advice.

More recalls from Torrent Pharma

All 84

Other Anagrelide recalls

All 3